References
- Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, . Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903–12.
- Klinkenberg-Knol EC, Jansen JB, Lamers CB, Nelis F, Meuwissen SG. Temporary cessation of long-term maintenance treatment with omeprazole in patients with H2-receptor-antagonist-resistant reflux oesophagitis. Effects on symptoms, endoscopy, serum gastrin, and gastric acid output. Scand J Gastroenterol 1990;25:1144–50.
- Nwokolo CU, Smith JT, Sawyerr AM, Pounder RE: Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade. Gut 1991;32:1455–60.
- El Omar E, Banerjee S, Wirz A, Penman I, Ardill JE, McColl KE: Marked rebound acid hypersecretion after treatment with ranitidine. Am J Gastroenterol 1996;91:355–9.
- Smith AD, Gillen D, Cochran KM, El Omar E, McColl KE. Dyspepsia on withdrawal of ranitidine in previously asymptomatic volunteers. Am J Gastroenterol 1999;94:1209–13.
- Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996;39:649–53.
- Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999;116:239–47.
- Lamberts R, Creutzfeldt W, Stockmann F, Jacubaschke U, Maas S, Brunner G. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion 1988;39:126–35.
- Klinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, . Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994;121:161–7.
- Sandvik AK, Brenna E, Waldum HL. Review article: the pharmacological inhibition of gastric acid secretion–tolerance and rebound. Aliment Pharmacol Ther 1997;11:1013–18.
- Gillen D, Wirz AA, McColl KE. Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment. Gastroenterology 2004;126:980–8.
- Hunfeld NG, Geus WP, Kuipers EJ. Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther 2007;25:39–46.
- Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009;137:80–7, 87.
- Niklasson A, Lindström L, Simrén M, Lindberg G, Björnsson E. Dyspeptic symptoms development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 2010;105:1531–7.
- Juul-Hansen P, Rydning A. Endoscopy-negative reflux disease: what is the value of a proton-pump inhibitor test in everyday clinical practice? Scand J Gastroenterol 2003;38:1200–3.
- el Omar EM, Banerjee S, Wirz A, McColl KE. The Glasgow Dyspepsia Severity Score–a tool for the global measurement of dyspepsia. Eur J Gastroenterol Hepatol 1996;8:967–71.
- Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 2005;21:149–54.
- Juul-Hansen P, Rydning A. On-demand PPI requirements in patients with endoscopy-negative GERD. J Clin Gastroenterol 2004;38:746–9.
- Waldum HL, Qvigstad G, Fossmark R, Kleveland PM, Sandvik AK: Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scand J Gastroenterol. 2010;45:389–94. Review.